

Via Email:
March 11, 2014

Andrew Behm, Pharm D
Vice President, Office of Clinical Evaluation and Policy
Express Scripts
6301 Cecilia Cir
Minneapolis, MN 55439

Dear Andrew,

I am writing to follow up on our correspondence late last year and to share a bit more about the Arthritis Foundation's future plans with regard to access and advocacy. As we discussed earlier, we appreciated your willingness last December to clarify your general formulary policies and to ease some of the constraints around a patient's ability to remain on an excluded drug. We have highlighted these positive outcomes on our website <http://www.arthritis.org/advocacy/advocate-news/express-scripts-drug-exclusions/> and through social media.

We also shared this outcome with our key nationwide volunteer leaders at our annual Leadership Retreat in February, and received strong support to elevate our advocacy efforts around access to care as one of our 4 key mission objectives going forward. We are currently recruiting for new staff leadership who will ensure that we proactively challenge barriers to access at the state and federal government levels and industry-wide with payers and providers as the need arises.

Part of our heightened commitment will be to seek ongoing input from consumers, from thought leaders in the benefits and access arena, and from the providers such as you who are so critical in this arena. Toward that end, we plan to refresh and update our coverage of the ESI excluded drug policies on arthritis.org and through social media around March 20th or 21st. This will include a call for consumers to share with us any experiences they have had recently with any of their health care providers or payers.

I wanted to give you an opportunity to share any updates from your end as part of this process. If anything has changed since our December correspondence, or if you have any additional information to share with us relative to how patients can access the drugs on your excluded list, please let me know no later than 5 p.m. Monday, March 17th. Please email your response to Patience White, M.D. at pwhite@arthritis.org and myself at apalmer@arthritis.org.

We look forward to continued collaboration and hope to hear from you soon. Thanks for your willingness to collaborate.

Sincerely,



Ann Palmer
President and CEO
Arthritis Foundation
National Office
apalmer@arthritis.org